Рет қаралды 643
LTR's new drug, Spontan, is a “first-in-class” rapid onset, on-demand therapeutic nasal spray for the treatment of ED. The company is nearing commercialization and just completed a successful capital raise that will propel the drug into Australian and US markets in the near future.
Here is my write-up on LTR Pharma simonschase.co... This is not investment advice. Do not rely on the contents of this video. Do your own due diligence.